Small Animal Imaging and Radiotherapy Facility

项目总结/摘要 在威斯康星州大学Carbone癌症中心（UWCCC）内，小动物成像和 放射治疗设施（SAIRF）提供创新的，最先进的，负担得起的，非侵入性的，高分辨率的， 为UWCCC成员提供体内和离体成像和放射治疗支持，这些成员利用小动物模型进行 research. SAIRF专家为研究人员提供指导，确保实验设计最适合于 解决他们的癌症问题。正电子发射/计算机断层扫描（PET/CT），单光子 发射计算机断层扫描（SPECT/CT）、磁共振成像（MRI）、超声/光声 (US/PA）、数字平面X射线和/或光学生物发光/荧光/近红外（NIR）成像 SAIRF提供了所有主要的小动物成像模式。此外，SAIRF还提供 放射治疗支持，为细胞、全身和CT引导的放射治疗提供X射线辐照器，以及 用于分析放射性组织/血液的生物分布、药理学和毒理学的专用设备 应用.此外，UWCCC成员可以选择他们想要的服务水平， 从图像递送/图像采集和重建到解释、分析和/或图形准备。在大多数 在某些情况下，专利代理是与合作者在内部开发和生产的，必要时， 获取商业试剂（Tc-99 m MDP、Lu-177 Lutathera、Ra-223二氯化物等）用于成像， 放射性核素治疗研究。SAIRF持有伞动物使用，生物安全和辐射安全协议，因此 确保成像和放射治疗研究的适当监管控制，同时最大限度地减少监管 对个别调查人员的负担。SAIRF支持新成像和治疗诊断的临床前开发 用于临床翻译的试剂。一个这样的代理，NM 404，在这里启动，并经历了广泛的 在转化为临床试验之前，在SAIRF内进行临床前评价。在当前的CCSG供资周期内， SAIRF为所有六个UWCCC项目的79个独特的UWCCC成员提供了关键的成像支持。 我们继续评估新的成像、放射治疗和相关技术，如果合适， 成员，制定计划，将这些新技术带入SAIRF。我们的具体目标是：1） UWCCC成员无缝访问和指导最先进的小动物癌症成像， 现有的放射治疗技术，以及2）临床前发现的基础设施和专业知识， 开发新的分子成像和治疗诊断癌症的药物。CCSG提供的资金 允许咨询、战略规划、培训、监管和质量监督，以支持我们的使命， 为UWCCC会员提供最高水平的服务，同时最大限度地降低成本。我们希望我们在 开发和评估新的成像和治疗剂，特别是我们自己开发的那些 会员资格以及对新治疗诊断剂的评估最终将允许个性化治疗 规划和改善癌症患者的生活质量和生存结果。

PROJECT SUMMARY / ABSTRACT Operating within the University of Wisconsin Carbone Cancer Center (UWCCC), the Small Animal Imaging & Radiotherapy Facility (SAIRF) provides innovative, state-of-the-art, affordable, noninvasive, high-resolution, in- vivo and ex-vivo imaging and radiotherapy support to UWCCC members who utilize small animal models in their research. SAIRF experts provide guidance to investigators ensuring the experimental design is best suited to address their cancer questions. Incorporating positron emission/computed tomography (PET/CT), single photon emission computed tomography (SPECT/CT), magnetic resonance imaging (MRI), ultrasound/photoacoustics (US/PA), digital planar X-ray, and/or optical bioluminescence/fluorescence/near-infrared (NIR) imaging modalities, SAIRF affords access to all major small animal imaging modalities. Additionally, SAIRF provides radiotherapy support, offering x-ray irradiators for cell, whole body, and CT-guided radiation therapy, and dedicated equipment to assay radioactive tissues/blood for biodistribution, pharmacology, and toxicology applications. Moreover, UWCCC members can select their desired level of service ranging from radiotherapy delivery/image acquisition and reconstruction, to interpretation, analysis, and/or figure preparation. In most cases, proprietary agents are developed and produced in-house with collaborators and when necessary, commercial agents (Tc-99m MDP, Lu-177 Lutathera, Ra-223 dichloride, etc) are acquired for imaging and radionuclide therapy studies. SAIRF holds umbrella animal use, biosafety, and radiation safety protocols, thus assuring appropriate regulatory control of imaging and radiotherapy studies while minimizing the regulatory burden on individual investigators. SAIRF supports the preclinical development of new imaging and theranostic agents intended for clinical translation. One such agent, NM404, initiated here and underwent extensive preclinical evaluation within SAIRF prior to translating to clinical trials. During the current CCSG funding cycle, SAIRF has provided critical imaging support to 79 unique UWCCC members across all six UWCCC programs. We continue to assess new imaging, radiotherapy and related technologies and, if suitable and relevant to the membership, develop a plan to bring such new technologies into SAIRF. Our specific aims are to provide: 1) UWCCC members seamless access and guidance to the most advanced small animal cancer imaging and radiotherapy technologies available, and 2) infrastructure and expertise for the preclinical discovery and development of new molecular imaging and theranostic cancer agents. Funding provided from the CCSG permits consultation, strategic planning, training, regulatory and quality oversight in support of our mission to serve the UWCCC membership at the highest level while minimizing costs. We expect that our role in development and evaluation of new imaging and therapy agents, especially those being developed by our own membership, as well as assessment of new theranostic agents, will ultimately permit personalized treatment planning and improve the quality of life and survival outcomes of cancer patients.